APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Syncytial Virus Vaccine for the Elderly

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Growth and Trends Forecast to 2032

27 December 2025104 pages

Choose your research edition.

Industry ResearchRespiratory Syncytial Virus Vaccine for the Elderly Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Syncytial Virus Vaccine for the Elderly Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Respiratory Syncytial Virus Vaccine for the Elderly market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Respiratory Syncytial Virus Vaccine for the Elderly market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Respiratory Syncytial Virus Vaccine for the Elderly market size, estimates, and forecasts are presented in terms of sales volume (Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Respiratory Syncytial Virus Vaccine for the Elderly market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Respiratory Syncytial Virus Vaccine for the Elderly.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Respiratory Syncytial Virus Vaccine for the Elderly market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Respiratory Syncytial Virus Vaccine for the Elderly Market by Company

GSK

Icosavax

Moderna

Pfizer

RNAimmune

Sanofi

Advaccine

Daiichi Sankyo

Immorna

Blue Lake Biotechnology

Clover Biopharma

Innorna

Starna Therapeutics

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type

Recombinant Protein Vaccine

Nucleic Acid Vaccines

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Respiratory Syncytial Virus Vaccine for the Elderly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Recombinant Protein Vaccine Table 2. Major Company of Nucleic Acid Vaccines Table 3. Major Company of Others Table 4. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Type (2021-2026) Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (US$ Million) Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Type (2021-2026) Table 9. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2026) & (US$/Unit) Table 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Type (2027-2032) Table 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (US$ Million) Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Type (2027-2032) Table 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2027-2032) & (US$/Unit) Table 15. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 16. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 18. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 20. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 22. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 24. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (US$ Million) Table 25. Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends Table 26. Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers Table 27. Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges Table 28. Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints Table 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company (2021-2026) Table 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Company (2021-2026) & (Units) Table 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Company (2021-2026) Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Respiratory Syncytial Virus Vaccine for the Elderly Major Company Production Sites and Headquarters Table 36. Global Respiratory Syncytial Virus Vaccine for the Elderly Company, Product Type & Application Table 37. Global Respiratory Syncytial Virus Vaccine for the Elderly Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Respiratory Syncytial Virus Vaccine for the Elderly by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (Units) Table 42. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Region (2021-2026) Table 43. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (US$ Million) Table 44. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Region (2021-2026) Table 45. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2027-2032) & (Units) Table 47. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Region (2027-2032) Table 48. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2027-2032) & (US$ Million) Table 49. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Region (2027-2032) Table 50. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 53. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Application (2021-2026) Table 54. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (US$ Million) Table 55. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Application (2021-2026) Table 56. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2026) & (US$/Unit) Table 57. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 58. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Application (2027-2032) Table 59. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (US$ Million) Table 60. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Application (2027-2032) Table 61. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2027-2032) & (US$/Unit) Table 62. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 63. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 65. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 67. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 69. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 71. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (US$ Million) Table 72. GSK Company Information Table 73. GSK Business Overview Table 74. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 76. GSK Recent Development Table 77. Icosavax Company Information Table 78. Icosavax Business Overview Table 79. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 81. Icosavax Recent Development Table 82. Moderna Company Information Table 83. Moderna Business Overview Table 84. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 86. Moderna Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 91. Pfizer Recent Development Table 92. RNAimmune Company Information Table 93. RNAimmune Business Overview Table 94. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 96. RNAimmune Recent Development Table 97. Sanofi Company Information Table 98. Sanofi Business Overview Table 99. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 101. Sanofi Recent Development Table 102. Advaccine Company Information Table 103. Advaccine Business Overview Table 104. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 106. Advaccine Recent Development Table 107. Daiichi Sankyo Company Information Table 108. Daiichi Sankyo Business Overview Table 109. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 111. Daiichi Sankyo Recent Development Table 112. Immorna Company Information Table 113. Immorna Business Overview Table 114. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 116. Immorna Recent Development Table 117. Blue Lake Biotechnology Company Information Table 118. Blue Lake Biotechnology Business Overview Table 119. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 121. Blue Lake Biotechnology Recent Development Table 122. Clover Biopharma Company Information Table 123. Clover Biopharma Business Overview Table 124. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 126. Clover Biopharma Recent Development Table 127. Innorna Company Information Table 128. Innorna Business Overview Table 129. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 131. Innorna Recent Development Table 132. Starna Therapeutics Company Information Table 133. Starna Therapeutics Business Overview Table 134. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 136. Starna Therapeutics Recent Development Table 137. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 138. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 139. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026) Table 140. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Units) Table 141. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Country (2027-2032) Table 142. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026) & (US$ Million) Table 144. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country (2021-2026) Table 145. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Share Forecast by Country (2027-2032) Table 147. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 148. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 149. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026) Table 150. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Units) Table 151. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Country (2027-2032) Table 152. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026) & (US$ Million) Table 154. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country (2021-2026) Table 155. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Share Forecast by Country (2027-2032) Table 157. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 158. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 159. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026) Table 160. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Units) Table 161. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Country (2027-2032) Table 162. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026) & (US$ Million) Table 164. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country (2021-2026) Table 165. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Share Forecast by Country (2027-2032) Table 167. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 168. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 169. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026) Table 170. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Units) Table 171. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Country (2027-2032) Table 172. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026) & (US$ Million) Table 174. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country (2021-2026) Table 175. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Share Forecast by Country (2027-2032) Table 177. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 178. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 179. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026) Table 180. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Units) Table 181. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Country (2027-2032) Table 182. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026) & (US$ Million) Table 184. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country (2021-2026) Table 185. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Share Forecast by Country (2027-2032) Table 187. Key Raw Materials Table 188. Raw Materials Key Suppliers Table 189. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List Table 190. Respiratory Syncytial Virus Vaccine for the Elderly Customers List Table 191. Research Programs/Design for This Report Table 192. Authors List of This Report Table 193. Secondary Sources Table 194. Primary Sources List of Figures Figure 1. Respiratory Syncytial Virus Vaccine for the Elderly Image Figure 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size (2021-2032) & (US$ Million) Figure 4. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2021-2032) & (Units) Figure 5. Recombinant Protein Vaccine Image Figure 6. Global Recombinant Protein Vaccine Sales YoY Growth (2021-2032) & (Units) Figure 7. Nucleic Acid Vaccines Image Figure 8. Global Nucleic Acid Vaccines Sales YoY Growth (2021-2032) & (Units) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (Units) Figure 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Type 2025 VS 2032 Figure 13. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Type in 2025 Figure 14. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Type in 2025 Figure 15. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Type in 2025 Figure 16. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Type in 2025 Figure 19. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Respiratory Syncytial Virus Vaccine for the Elderly Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (Units) Figure 27. Centers for Disease Control and Prevention Image Figure 28. Global Centers for Disease Control and Prevention Sales YoY Growth (2021-2032) & (Units) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (Units) Figure 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Application 2025 VS 2032 Figure 33. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Application in 2025 Figure 34. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Application in 2025 Figure 35. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Application in 2025 Figure 36. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Application in 2025 Figure 39. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share in Value by Application in 2025 Figure 43. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 44. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 48. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 52. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 56. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 60. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Protein Vaccine
  • Nucleic Acid Vaccines
  • Others
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • GSK
  • Icosavax
  • Moderna
  • Pfizer
  • RNAimmune
  • Sanofi
  • Advaccine
  • Daiichi Sankyo
  • Immorna
  • Blue Lake Biotechnology
  • Clover Biopharma
  • Innorna
  • Starna Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Respiratory Syncytial Virus Vaccine for the Elderly Market by Type
  6. 1.3.1 Recombinant Protein Vaccine
  7. 1.3.2 Nucleic Acid Vaccines
  8. 1.3.3 Others
  9. 1.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type
  10. 1.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
  2. 2.2 Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers
  3. 2.3 Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges
  4. 2.4 Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2026)
  2. 3.2 Global Top Players by Respiratory Syncytial Virus Vaccine for the Elderly Sales (2021-2026)
  3. 3.3 Global Top Players by Respiratory Syncytial Virus Vaccine for the Elderly Price (2021-2026)
  4. 3.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Major Company Production Sites & Headquarters
  6. 3.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Company, Product Type & Application
  7. 3.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Respiratory Syncytial Virus Vaccine for the Elderly Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Respiratory Syncytial Virus Vaccine for the Elderly Tier 1, Tier 2, and Tier 3
4 Respiratory Syncytial Virus Vaccine for the Elderly Regional Status and Outlook
  1. 4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Historic Market Size by Region
  3. 4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecasted Market Size by Region
  7. 4.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Respiratory Syncytial Virus Vaccine for the Elderly by Application
  1. 5.1 Respiratory Syncytial Virus Vaccine for the Elderly Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Centers for Disease Control and Prevention
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application
  6. 5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 GSK
  2. 6.1.1 GSK Company Information
  3. 6.1.2 GSK Business Overview
  4. 6.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  6. 6.1.5 GSK Recent Developments
  7. 6.2 Icosavax
  8. 6.2.1 Icosavax Company Information
  9. 6.2.2 Icosavax Business Overview
  10. 6.2.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  12. 6.2.5 Icosavax Recent Developments
  13. 6.3 Moderna
  14. 6.3.1 Moderna Company Information
  15. 6.3.2 Moderna Business Overview
  16. 6.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  18. 6.3.5 Moderna Recent Developments
  19. 6.4 Pfizer
  20. 6.4.1 Pfizer Company Information
  21. 6.4.2 Pfizer Business Overview
  22. 6.4.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  24. 6.4.5 Pfizer Recent Developments
  25. 6.5 RNAimmune
  26. 6.5.1 RNAimmune Company Information
  27. 6.5.2 RNAimmune Business Overview
  28. 6.5.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  30. 6.5.5 RNAimmune Recent Developments
  31. 6.6 Sanofi
  32. 6.6.1 Sanofi Company Information
  33. 6.6.2 Sanofi Business Overview
  34. 6.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  36. 6.6.5 Sanofi Recent Developments
  37. 6.7 Advaccine
  38. 6.7.1 Advaccine Company Information
  39. 6.7.2 Advaccine Business Overview
  40. 6.7.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  42. 6.7.5 Advaccine Recent Developments
  43. 6.8 Daiichi Sankyo
  44. 6.8.1 Daiichi Sankyo Company Information
  45. 6.8.2 Daiichi Sankyo Business Overview
  46. 6.8.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  48. 6.8.5 Daiichi Sankyo Recent Developments
  49. 6.9 Immorna
  50. 6.9.1 Immorna Company Information
  51. 6.9.2 Immorna Business Overview
  52. 6.9.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  54. 6.9.5 Immorna Recent Developments
  55. 6.10 Blue Lake Biotechnology
  56. 6.10.1 Blue Lake Biotechnology Company Information
  57. 6.10.2 Blue Lake Biotechnology Business Overview
  58. 6.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  60. 6.10.5 Blue Lake Biotechnology Recent Developments
  61. 6.11 Clover Biopharma
  62. 6.11.1 Clover Biopharma Company Information
  63. 6.11.2 Clover Biopharma Business Overview
  64. 6.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  66. 6.11.5 Clover Biopharma Recent Developments
  67. 6.12 Innorna
  68. 6.12.1 Innorna Company Information
  69. 6.12.2 Innorna Business Overview
  70. 6.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  72. 6.12.5 Innorna Recent Developments
  73. 6.13 Starna Therapeutics
  74. 6.13.1 Starna Therapeutics Company Information
  75. 6.13.2 Starna Therapeutics Business Overview
  76. 6.13.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  78. 6.13.5 Starna Therapeutics Recent Developments
7 North America by Country
  1. 7.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country
  2. 7.1.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
  4. 7.1.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032)
  5. 7.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  6. 7.2.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026)
  8. 7.2.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country
  2. 8.1.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
  4. 8.1.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  6. 8.2.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026)
  8. 8.2.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country
  2. 9.1.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  6. 9.2.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country
  2. 10.1.1 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
  4. 10.1.3 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032)
  5. 10.2 South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  6. 10.2.1 South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026)
  8. 10.2.3 South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country
  2. 11.1.1 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  6. 11.2.1 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Analysis
  2. 12.1.1 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process
  7. 12.2 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
  10. 12.2.3 Respiratory Syncytial Virus Vaccine for the Elderly Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst